Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$4.12
-4.1%
$5.16
$2.94
▼
$6.53
$1.24B0.24789,350 shs725,365 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$31.78
-2.3%
$32.17
$21.86
▼
$45.42
$6.58B0.951.50 million shs394,633 shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$97.10
-0.8%
$81.85
$19.25
▼
$112.79
$6.35B2.021.11 million shs533,947 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$286.87
0.0%
$302.30
$175.89
▼
$326.63
$5.74B1.16263,654 shs169,474 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
-5.71%-8.14%-16.21%-3.16%-17.97%
Immunovant, Inc. stock logo
IMVT
Immunovant
-2.05%-7.30%+13.64%-26.77%+40.29%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+0.21%-9.45%+5.43%+155.72%+401.88%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-3.94%-9.27%-6.35%+0.23%+39.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$4.12
-4.1%
$5.16
$2.94
▼
$6.53
$1.24B0.24789,350 shs725,365 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$31.78
-2.3%
$32.17
$21.86
▼
$45.42
$6.58B0.951.50 million shs394,633 shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$97.10
-0.8%
$81.85
$19.25
▼
$112.79
$6.35B2.021.11 million shs533,947 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$286.87
0.0%
$302.30
$175.89
▼
$326.63
$5.74B1.16263,654 shs169,474 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
-5.71%-8.14%-16.21%-3.16%-17.97%
Immunovant, Inc. stock logo
IMVT
Immunovant
-2.05%-7.30%+13.64%-26.77%+40.29%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+0.21%-9.45%+5.43%+155.72%+401.88%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-3.94%-9.27%-6.35%+0.23%+39.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVO
Alvotech
2.57
Moderate Buy$8.40104.13% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.62
Moderate Buy$44.6040.35% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.63
Moderate Buy$117.8621.37% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
2.89
Moderate Buy$355.3823.88% Upside

Current Analyst Ratings Breakdown

Latest ALVO, LGND, IMVT, and KOD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/19/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Boost Price TargetOverweight$124.00 ➝ $128.00
11/18/2026
Alvotech stock logo
ALVO
Alvotech
UpgradeStrong Sell ➝ Hold
11/13/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Boost Price TargetBuy$120.00 ➝ $150.00
11/11/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Boost Price TargetOverweight$345.00 ➝ $350.00
11/10/2026
Alvotech stock logo
ALVO
Alvotech
Initiated CoverageBuy$9.00
11/10/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetHold$30.00 ➝ $33.00
11/10/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetOverweight$45.00 ➝ $47.00
11/5/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Boost Price TargetBuy$397.00 ➝ $402.00
11/4/2026
Alvotech stock logo
ALVO
Alvotech
UpgradeSell (E+) ➝ Sell (D-)
11/2/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
DowngradeBuy (B) ➝ Hold (C)
10/30/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Boost Price TargetOutperform$345.00 ➝ $357.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVO
Alvotech
$588.90M2.11$0.20 per share20.88($0.89) per share-4.62
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$3.17 per shareN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$0.19 per shareN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$268.09M21.40$7.54 per share38.04$48.08 per share5.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVO
Alvotech
$27.92M-$0.82N/A15.24N/A-50.62%N/A-11.71%N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.56N/AN/AN/AN/A-63.01%-56.19%2/5/2027 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$229.97M-$4.08N/AN/AN/AN/A-287.64%-87.83%N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$2.24128.0735.505.2220.27%5.22%2.74%N/A

Latest ALVO, LGND, IMVT, and KOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.06-$1.05+$0.01-$1.05N/AN/A
11/11/2026Q3 2026
Alvotech stock logo
ALVO
Alvotech
-$0.0297-$0.03-$0.0003-$0.24$123.45 million$111.60 million
11/9/2026Q2 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.7370-$0.47+$0.2670-$0.4060N/AN/A
10/29/2026Q3 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$2.33$2.67+$0.34-$1.43$77.00 million$78.75 million
8/20/2026Q2 2026
Alvotech stock logo
ALVO
Alvotech
-$0.0526-$0.11-$0.0574-$0.2230$103.00 million$106.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alvotech stock logo
ALVO
Alvotech
N/A
1.78
0.94
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.31
7.31
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
1.70
1.70
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.71
1.22
1.19

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVO
Alvotech
0.46%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
44.40%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVO
Alvotech
1,460301.81 million300.42 millionNot Optionable
Immunovant, Inc. stock logo
IMVT
Immunovant
315206.95 million203.02 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
12465.40 million36.36 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4720.00 million18.88 millionOptionable

Recent News About These Companies

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $350.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVO

$4.12 -0.18 (-4.08%)
Closing price 03:58 PM Eastern
Extended Trading
$4.12 +0.01 (+0.24%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$31.78 -0.74 (-2.28%)
Closing price 03:58 PM Eastern
Extended Trading
$31.76 -0.01 (-0.04%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$97.10 -0.80 (-0.81%)
Closing price 03:58 PM Eastern
Extended Trading
$97.19 +0.09 (+0.09%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$286.87 -0.07 (-0.02%)
Closing price 03:59 PM Eastern
Extended Trading
$287.22 +0.35 (+0.12%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.